Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics

Fennec Pharmaceuticals Inc. (FENC): $9.61

0.10 (+1.05%)

POWR Rating

Component Grades













FENC Stock Price Chart Interactive Chart >

Price chart for FENC

FENC Price/Volume Stats

Current price $9.61 52-week high $9.89
Prev. close $9.51 52-week low $3.82
Day low $9.12 Volume 70,600
Day high $9.89 Avg. volume 73,599
50-day MA $8.19 Dividend yield N/A
200-day MA $6.57 Market Cap 252.15M

Fennec Pharmaceuticals Inc. (FENC) Company Bio

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Latest News Stream

Event/Time News Detail
Loading, please wait...

FENC Latest Social Stream

Loading social stream, please wait...

View Full FENC Social Stream

Latest FENC News From Around the Web

Below are the latest news stories about FENNEC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FENC as an investment opportunity.

Maxim Group Keeps Their Buy Rating on Fennec Pharmaceuticals (FENC)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Fennec Pharmaceuticals (FENC - Research Report), with a price target of $15.00. The company's shares opened today at $7.93.According to TipRanks, McCarthy is an analyst with an average return of -38.1% and a 14.47% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.Fennec Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $15.75.See the top stocks recommended by analysts >>The company has a one-year high of $10.05 and a one-year low of $3.82.

Carrie Williams on TipRanks | November 15, 2022

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK® in October 2022 ~ ~ Closed $25 Million in Funding from Petrichor to Support the U.S. Commercialization of PEDMARK®, With the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 11

Yahoo | November 11, 2022

Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Are Analysts Optimistic?

Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is possibly approaching a major achievement in its business, so we would...

Yahoo | November 1, 2022

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient Services, Including Access to Care Coordinators, Financial and Prescription Drug Support ~ RESEARCH TRIANGLE PARK, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the U.S. commercial launch an

Yahoo | October 17, 2022

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today

Yahoo | September 26, 2022

Read More 'FENC' Stories Here

FENC Price Returns

1-mo 14.13%
3-mo 37.29%
6-mo 64.84%
1-year 101.05%
3-year 206.98%
5-year 98.35%
YTD 118.41%
2021 18.12%
2020 14.79%
2019 1.72%
2018 -36.33%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6965 seconds.